Noven

What Noven does

Noven Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company focused on the development, manufacture, and commercialization of prescription transdermal drug delivery systems. Founded in 1987 in Miami, Florida and acquired by Japan's Hisamitsu Pharmaceutical Co., Inc. in February 2009, Noven operates as the US prescription pharmaceuticals platform of Hisamitsu, the world's largest transdermal patch manufacturer. The company is headquartered in Miami, with a Northeast operations and business development office in Jersey City, New Jersey, and employs over 300 colleagues.

Noven's commercial portfolio consists of three FDA-approved branded transdermal patches: XELSTRYM (dextroamphetamine) for ADHD, SECUADO (asenapine) for schizophrenia, and COMBIPATCH (estradiol/norethindrone acetate) for menopausal symptoms. Two authorized generics — Estradiol Transdermal System (generic to Minivelle) and Methylphenidate Transdermal System (generic to Daytrana) — are distributed through Prasco and Padagis, respectively, via the company's generic division, Grove Pharmaceuticals. The product development and partnering pages describe additional capabilities spanning passive and active transdermal systems, topicals, injectables, and oral/sublingual formulations, including the HalDisc microneedle technology developed by Hisamitsu.

Noven generates revenue by marketing and selling prescription pharmaceutical products through its wholly-owned subsidiary, Noven Therapeutics, LLC, distributing via US pharmacy channels that require valid prescriptions. The Noven Care Access Network (Noven C.A.N.) provides patient support including product information, coverage assistance, and co-pay eligibility. Manufacturing is conducted at FDA- and DEA-approved facilities in Miami with a production capacity of several hundred million patches per year, supporting both Noven's own commercial portfolio and contract or partnered volumes. Customer end-users are individual patients across two primary therapeutic segments — Mental Health (ADHD, schizophrenia) and Women's Health (menopause) — reached indirectly through healthcare provider prescriptions.

Name

Noven

Legal name

Noven Pharmaceuticals, Inc.

Website

https://noven.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Noven Pharmaceuticals is a US specialty pharmaceutical company that develops, manufactures, and commercializes FDA-approved prescription transdermal patches for ADHD, schizophrenia, and menopausal symptoms, operating as the US platform of Japan's Hisamitsu and serving patients through US pharmacy channels.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Transdermal Drug Delivery)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Transdermal drug delivery
• Specialty pharmaceuticals
• Transdermal patches
• Hormone replacement therapy
• Psychiatric patch therapy

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceutical Products: Revenue from research, development, manufacture, marketing, and sale of prescription pharmaceutical products including transdermal patches. Products are marketed through Noven Therapeutics, LLC.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Noven develops, manufactures, and commercializes prescription transdermal drug delivery systems (patches) focused on mental health (ADHD, schizophrenia) and women's health (menopausal hormone therapy). Its commercial portfolio includes XELSTRYM, SECUADO, COMBIPATCH, and authorized generic Estradiol Transdermal System and Methylphenidate Transdermal System products, marketed through its subsidiary Noven Therapeutics, LLC and distributed via U.S. pharmacy channels.

Product overview

Noven is a fully integrated specialty pharmaceutical company focused on transdermal drug delivery systems (patches). The company's commercial portfolio consists of three FDA-approved transdermal patch products: XELSTRYM® (dextroamphetamine) for ADHD, SECUADO® (asenapine) for schizophrenia, and COMBIPATCH® (estradiol/norethindrone) for menopausal symptoms. Noven also markets authorized generic versions of previously branded products including Methylphenidate Transdermal System (generic to DAYTRANA®) and Estradiol Transdermal System (generic to MINIVELLE®). Products are marketed through Noven Therapeutics, LLC, with authorized generics distributed through Grove Pharmaceuticals (generic division) and Prasco. The company collaborates with parent company Hisamitsu on transdermal technology development including passive TDDS and active technologies like HalDisc® microneedle technology.

Differentiator

Problem solved

Functional benefit

Products and services

• XELSTRYM® (dextroamphetamine) transdermal system, CII Once-daily transdermal patch for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older; the first and only FDA-approved amphetamine patch.
• SECUADO® (asenapine) transdermal system Transdermal patch for the treatment of adults with schizophrenia; the first-and-only transdermal patch approved for schizophrenia.
• COMBIPATCH® (estradiol/norethindrone acetate transdermal system) Combination hormone replacement transdermal patch containing estradiol and norethindrone acetate for women experiencing menopausal symptoms; the first combination (two-drug) transdermal patch.
• Estradiol Transdermal System (Authorized Generic to MINIVELLE®) FDA-approved authorized generic version of MINIVELLE® estradiol transdermal system for menopausal symptoms, marketed by Grove Pharmaceuticals (Noven's authorized generic division) and distributed through Prasco.
• Methylphenidate Transdermal System (Authorized Generic to DAYTRANA®) FDA-approved authorized generic version of DAYTRANA® (methylphenidate transdermal system), CII for ADHD, made in the same manufacturing plant, conditions, processes, and formulation as the branded Daytrana product; distributed through Padagis.
• Mindful Patch Companion App Optional companion mobile application for patients with ADHD using XELSTRYM® patch; debuted at APSARD 2025.

Quantifiable outcome

• Several hundred million patches per year manufacturing capacity
• +1 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered historical, flagship and core.

• ShionogihistoricalGTM or Marketing Partner · 13 January 2014Co-promotion agreement for Brisdelle (paroxetine) capsules - first FDA-approved non-hormonal treatment for hot flashes. Noven subsequently transferred Brisdelle and Pexeva to Sebela Pharmaceuticals in 2016.
• ShirehistoricalStrategic or Co-development Partner · 1 October 2010Noven reacquired Daytrana (methylphenidate transdermal system) from Shire in October 2010. Previously Shire and Noven had launched Daytrana together in February 2006.
• Hisamitsu Pharmaceutical Co., Inc.flagshipStrategic or Co-development PartnerHisamitsu is the world's largest manufacturer of transdermal patches. Noven is a wholly owned subsidiary and serves as Hisamitsu's platform in US prescription pharmaceuticals. They collaborate across product development, manufacturing, and business development. Hisamitsu's Salonpas brand is the world's number one OTC topical analgesic patch brand.
• Prasco LaboratoriescoreChannel Partner/ Reseller/ DistributorPrasco distributes Noven's authorized generic Estradiol Transdermal System (generic to MINIVELLE) through US pharmacies.
• PadagiscoreChannel Partner/ Reseller/ DistributorPadagis manufactures and distributes the Methylphenidate Transdermal System authorized generic (formerly DAYTRANA). Contact: 800-775-2054.
• Sebela PharmaceuticalshistoricalStrategic or Co-development PartnerAcquired Brisdelle (paroxetine) and Pexeva (paroxetine) from Noven in June 2016.
• Grove PharmaceuticalscoreChannel Partner/ Reseller/ DistributorGeneric division of Noven Therapeutics, LLC. Markets authorized generic Estradiol Transdermal System and other generic products.
• FDA (Supply Coordination)coreStrategic or Co-development PartnerFDA coordinating with Noven and other manufacturers (Amneal, Zydus, Sandoz, Viatris) to boost supply amid estrogen patch shortages following FDA's November decision to lift black box warnings from hormone replacement therapy.

Scale indicators6 records

Recent moves10 records

Expansion highlights5 records

Market position

Strengths4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/noven-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Noven